Navigation Links
Anemia Drug May Worsen Heart Attacks
Date:5/11/2011

By Steven Reinberg
HealthDay Reporter

TUESDAY, May 10 (HealthDay News) -- People given a drug known as erythropoietin alfa after a heart attack may experience new heart problems and even greater cardiac damage from the attack, a new study finds.

The drug, which stimulates red blood cells, has been used in some heart attack patients because certain studies suggested it might reduce the extent of heart attack damage and improve heart function, the researchers explained.

The study was published in the May 11 issue of the Journal of the American Medical Association.

"This study shows that erythropoietin should only be used with caution in patients with recent heart attacks," said Dr. Deepak L. Bhatt, chief of cardiology at the VA Boston Healthcare System, who was not involved in the study.

In fact, "there are hints in this study that the use of erythropoietin might have adverse cardiac effects," said Bhatt, who is also an associate professor of medicine at Harvard Medical School and the author of an accompanying editorial in the journal. This does not mean the drug doesn't have its place, for example, to help reduce transfusions in people with low blood counts, he added.

Known as erythropoiesis-stimulating agents (ESAs), erythropoietin drugs include Procrit and Epogen. They are typically used to treat anemia in cancer patients and to lower the risk of transfusions.

For the new study, dubbed the REVEAL trial, 222 heart attack patients in multiple centers across the United States were randomly assigned to receive erythropoietin alfa or a placebo after undergoing a balloon angioplasty or stent placement to open blocked heart vessels.

The patients had all suffered the most critical type of heart attack -- an ST segment elevation myocardial infarction, or STEMI. Because these patients are in danger of cardiac tissue death due to a local lack of oxygen (infarct) and other changes that increase the chance of heart failure and death, the researchers wanted to see whether erythropoietin alfa might have a protective effect.

The trial was led by Dr. Samer S. Najjar, of the Med-Star Health Research Institute at the Washington Hospital Center, in Washington, D.C. As a phase 2, randomized, double-blind trial involving a placebo and control group, in which neither the patients nor the researchers knew who was getting medication or the sham treatment, it is the type of study considered the gold standard of research.

The heart attack patients taking erythropoietin alfa received an intravenous dose of the medication four hours after a primary or rescue angioplasty or stent procedure; the control group received a saline infusion. Each patient underwent two cardiovascular magnetic resonance imaging scans, one before and one after treatment with erythropoietin alfa or the placebo.

The researchers found the size of the damaged area of the heart remained the same after each scan in both the erythropoietin alfa and placebo groups.

However, among patients 70 and older given erythropoietin alfa, heart damage actually increased over the first week after treatment, the researchers said.

Moreover, five patients receiving erythropoietin alfa either died, had another heart attack or had a blockage in the stent placed during angioplasty. None of the patients receiving placebo had these problems, the researchers said.

This is not the first time Procrit and other ESAs have been linked to serious adverse events. Last year, problems with ESAs prompted the U.S. Food and Drug Administration to require tighter guidelines on them for cancer patients because of the increased risk of stroke, heart failure, tumor promotion and death seen among those taking them.

Commenting on the study, Dr. Gregg Fonarow, the associate chief of cardiology at UCLA's David Geffen School of Medicine, said that "there has been substantial interest in the development of cardioprotective agents which could be administered during acute myocardial infarction (heart attack)."

There has been a growing body of experimental data that suggests erythropoietin may have anti-inflammatory properties and other qualities that could protect the heart, but earlier studies evaluating the effects of erythropoietin have been small, with conflicting results, he added.

"These findings, together with prior studies, suggest that there are not clinically relevant cardioprotective effects with erythropoietin-stimulating agents in patients with acute myocardial infarction," Fonarow said.

More information

For more information on ESAs, visit the U.S. Food and Drug Administration.

SOURCES: Deepak L. Bhatt, M.D., M.P.H., chief of cardiology, VA Boston Healthcare System Director, Integrated Interventional Cardiovascular Program, Brigham and Women's Hospital & VA Boston Healthcare System, associate professor of medicine, Harvard Medical School, Boston; Gregg Fonarow, M.D., associate chief, cardiology, David Geffen School of Medicine, University of California, Los Angeles; May 11, 2011, Journal of the American Medical Association


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Tightens Controls on Anemia Drugs
2. For Some on Dialysis, Anemia Drugs Pose Risks
3. Anemia tougher to tackle in black children with kidney disease
4. Anemia Harder to Treat in Black Children With Kidney Disease
5. Anemia Drugs Hold Dangers for Kidney Patients
6. OHSU joins forces with UO, Harvard to accelerate Fanconi anemia research
7. Stroke prevention study in children with sickle cell anemia, iron overload stopped early
8. Anemia Drugs Could Pose Threat to Some Kidney Patients
9. FDA Advisers Back Anemia Drugs for Kidney Patients
10. Use Anemia Drugs for Cancer Patients With Caution, Experts Say
11. Mathematical model of the life cycle of red blood cells may predict risk of anemia
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Anemia Drug May Worsen Heart Attacks
(Date:6/23/2017)... VA (PRWEB) , ... June 23, 2017 , ... ... of what is needed and will ultimately do significant harm to people with ... to everyone. , "While it leaves in place the Affordable Care Act ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... plastic surgeon practicing in Newburgh, New York, has recently begun offering three new ... to offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... cooking is essential, and two new videos highlight the importance of correctly using ... Christine Bruhn, Ph.D., who has done extensive research on consumer food safety habits. ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance ... With the Federal Emergency Management Agency’s (FEMA) recent update of flood zones, more ... 2012, the Biggert-Waters Act was enacted to reflect the actual risk in flood ...
(Date:6/23/2017)... ... June 23, 2017 , ... All-Star Insurance, a family managed agency that offers ... Texas, is announcing the launch of a new charity drive to benefit women in ... United States reveal that an estimated 252, 710 new cases of invasive or high ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... 1, 2017 Nutriceutical Holdings (NH), parent company ... (VRS), and KD Pharma Group have decided to join ... KD Pharma Group. KD Pharma Group will become the ... acquire the entire company. "We believe we ... committed to growing the NH companies by providing us ...
(Date:5/26/2017)... 26, 2017  Endo International plc (NASDAQ: ENDP ... CEO, will represent the Company in a fireside chat at ... Tuesday, June 13, 2017 at 10:40 a.m. PT / 1:40 ... in Rancho Palos Verdes, CA. ... will be available on the Company,s website at http://www.endo.com/investors/overview ...
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
Breaking Medicine Technology: